DiscoverIron Direct Primary Care Podcast
Iron Direct Primary Care Podcast
Claim Ownership

Iron Direct Primary Care Podcast

Author: Stefan Hartmann

Subscribed: 2Played: 8
Share

Description

Learn Functional Medicine with Iron DPC and more.
For providers and patients alike.

For patients: register on ironDPC.com

For providers wanting to learn HRT for primary care register at HRTPCP.com
42 Episodes
Reverse
In adults with type 2 diabetes, retatrutide lowered A1C by an average of 2.2% vs. 1.8% with Ozempic 2 mg at 80 weeksParticipants taking retatrutide lost an average of 44 lbs to 47 lbs (20% to 21%) vs. 21 lbs (9%) with Ozempic 2 mg at 80 weeksTRANSCEND-T2D-2 marks the sixth Phase 3 trial in which retatrutide has delivered powerful efficacy, reinforcing its potential to transform cardiometabolic care
What happens when two people who were deep in the keto and carnivore world change their minds—not because of trends, but because patients started having heart attacks and the data became undeniable? Sarah and Stefan discuss the backlash from the keto/carnivore community after Stefan's viral X post: https://x.com/ironDPC/status/2105632631744266514?s=20 Dr. Sarah Zaldivar left strict carnivore after years of advocacy and saw better recovery, performance, and mood once she strategically reintroduced carbs.Stefan Hartmann went from lipid denialist to advocating aggressive ApoB lowering after watching ‘optimized’ patients still get events.They took the heat from their own communities. This is the raw conversation about dogma, lipids, and what the evidence actually forces you to accept.
Can millennials become the longest-lived generation in history—and maintain their strength, independence, and vitality along the way?In this lecture for the Chronic Disease Prevention & Management Group, Stefan Hartmann, PA-C, CEO of Iron Direct Primary Care in Melbourne, Florida, presents his approach to anti-aging medicine as comprehensive primary care.The central idea: intervene earlier, reduce decades of exposure to modifiable risk factors, and build physical capacity before disease and functional decline become established.Topics include:• America’s leading causes of death and opportunities for prevention• ApoB below 70 mg/dL as a proposed target for earlier cardiovascular prevention• Intensive lipid lowering, plaque regression, and findings from FOURIER-OLE, PACMAN-AMI, and HUYGENS• Earlier blood pressure management and protection of cardiovascular and kidney health• GLP-1–based therapies and advances in metabolic disease treatment• Resistance training, adequate protein, and preserving muscle throughout life• Proactive hormone assessment and individualized HRT, including care during perimenopause• Brain health, frailty prevention, and maintaining independence• Emerging evidence surrounding sauna, cold exposure, and red light therapyThis lecture explores established clinical evidence alongside the rationale—and remaining uncertainties—behind more proactive longevity strategies.Our ambition is more years of health, physical capability, and participation in life.Presented by Stefan Hartmann, PA-CCEO, Iron Direct Primary CareMelbourne, FloridaLearn more: https://www.irondpc.comInstagram: @irondirectprimarycareTo learn HRT in primary care check out HRTPCP.comEducational content. Treatment decisions require individualized assessment.#Longevity #AntiAgingMedicine #PrimaryCare #ApoB #HormoneTherapy
What happens when addiction medicine, primary care, and national drug policy collide? On this episode of the Iron Direct Primary Care Podcast, Stefan Hartmann, PA-C sits down with Dr. Andrea Barthwell, one of the most experienced voices in American addiction medicine.Dr. Barthwell is a past president of the American Society of Addiction Medicine (ASAM) and served in the George W. Bush White House as Deputy Director for Demand Reduction at the Office of National Drug Control Policy (ONDCP). She is the founder of Encounter Medical Group and Two Dreams and was the founding chair of the $100 million Foundation for Opioid Response Efforts (FORE).This wasn't a conventional addiction-medicine interview.We discuss how American drug policy has changed—from the Bush-era War on Drugs and demand-reduction strategy to modern approaches emphasizing legalization, decriminalization, and harm reduction—and what decades of experience can teach us about the consequences of those choices.A major part of the conversation focuses on marijuana and the increasing tendency to treat cannabis as medicine or routine self-care. Dr. Barthwell explains her concerns about the medicalization of marijuana, particularly when patients assume that legalization or a medical-marijuana designation automatically means strong evidence of therapeutic benefit or long-term safety.We also go deep into something primary-care clinicians deal with every day:Sleep.Patients frequently arrive already using or requestingmedications such as:Eszopiclone (Lunesta) Trazodone GabapentinHydroxyzine Diphenhydramine (Benadryl) Atypical antipsychoticsWe discuss the tradeoffs of using psychoactive medications simply to make someone sleep, how dependence and substance-use history should change prescribing decisions, and why insomnia deserves more thoughtful evaluation than simply adding another sedating drug.We also discuss the role of primary care in identifying addiction early. Substance-use disorders do not always walk into the office announcing themselves. Alcohol, cannabis, prescription medications, stimulants, and opioids can become part of a patient's routine long before anyone formally identifies a disorder.Finally, Dr. Barthwell explains why she remains strongly supportive of evidence-based medications for opioid use disorder, including methadone and buprenorphine, and why these therapies should be viewed as medical treatment rather than simply substituting one drug for another.If you would like to learn anti aging medicine for primary care check out HRTPCP.COM to take our HRT courseConnect with Dr. Barthwell at https://www.linkedin.com/in/drandreabarthwell/andtwodreams.com
To download and read the full paper check out https://www.irondpc.com/blogTo learn HRT go to HRTPCP.com AbstractBackgroundInsulin resistance and elevated apolipoprotein B (ApoB) frequently coexist in adverse cardiometabolic phenotypes. However, biologic association does not establish that fasting insulin and ApoB provide interchangeable clinical information. Whether individuals with low fasting insulin reliably demonstrate low ApoB in routine primary care remains uncertain.ObjectiveTo characterize the relationship and discordance between fasting insulin and ApoB among adults undergoing same-day testing in a real-world primary care population, with secondary analyses incorporating hemoglobin A1c and exploratory analyses of female age, LC-MS estradiol, and ApoB.MethodsWe conducted a retrospective observational analysis of routinely collected laboratory data from a community-based primary care practice. The primary cohort included adults aged 18 years or older with numeric ApoB and explicitly fasting insulin measurements obtained on the exact same collection date. Each patient contributed the first chronologically qualifying paired measurement to the primary analysis. The primary outcome was the Spearman correlation between fasting insulin and ApoB. Secondary analyses assessed ApoB prevalence across fasting-insulin quartiles and multivariable associations adjusted for age and sex. Hemoglobin A1c was incorporated as an additional glycemic covariate in participants with same-day measurements. An exploratory female analysis evaluated exact same-day LC-MS estradiol and ApoB measurements.ResultsThe primary cohort included 365 adults (62.7% male; mean age 48.0 plus or minus 13.0 years). Mean ApoB was 100.9 plus or minus 28.6 mg/dL, and median fasting insulin was 7.7 (IQR 5.1 to 12.6). Fasting insulin and ApoB were positively but weakly correlated (Spearman rho = 0.156; p = 0.0029). After adjustment for age and sex, each doubling of fasting insulin was associated with 4.19 mg/dL higher ApoB (95% CI 1.46 to 6.93; p = 0.0028).Despite this association, substantial discordance was observed. Among participants in the lowest fasting-insulin quartile, 59.8% had ApoB of 90 mg/dL or higher and 44.6% had ApoB of 100 mg/dL or higher.Hemoglobin A1c was available on the same date in 347 participants (95.1%). After additional adjustment for A1c, each doubling of fasting insulin remained associated with 3.47 mg/dL higher ApoB (95% CI 0.66 to 6.28; p = 0.015). Among 79 adults with both A1c less than 5.7% and fasting insulin in the lowest quartile, 60.8% had ApoB of 90 mg/dL or higher and 46.8% had ApoB of 100 mg/dL or higher.In an exploratory analysis of 133 adult women with exact same-day ApoB and LC-MS estradiol measurements, estradiol was modestly inversely associated with ApoB in unadjusted analysis (Spearman rho = -0.182; p = 0.036), but this association was attenuated after adjustment for age.ConclusionsFasting insulin was positively but weakly associated with ApoB in this real-world primary care population. Elevated ApoB remained common among patients with low fasting insulin, including patients who simultaneously had A1c less than 5.7%. These findings suggest that fasting insulin, chronic glycemia, and ApoB provide overlapping but substantially nonredundant information. Exploratory female analyses demonstrated opposing age-related trajectories of estradiol and ApoB, although a single contemporaneous estradiol measurement did not independently explain ApoB after adjustment for age.Keywords: apolipoprotein B; ApoB; fasting insulin; hemoglobin A1c; insulin resistance; estradiol; cardiometabolic risk; primary care; discordance
loading
Comments